Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.290
-0.060 (-4.44%)
At close: Apr 24, 2024, 4:00 PM
1.330
+0.040 (3.10%)
After-hours: Apr 24, 2024, 7:09 PM EDT
Ikena Oncology Stock Forecast
IKNA's stock price has decreased by -73.94% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Ikena Oncology stock have an average target of 10.67, with a low estimate of 8.00 and a high estimate of 13. The average target predicts an increase of 727.13% from the current stock price of 1.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2024.
Analyst Ratings
The average analyst rating for Ikena Oncology stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +752.71% | Mar 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +752.71% | Mar 12, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +520.16% | Jan 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +752.71% | Jan 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $11 | Strong Buy | Maintains | $18 → $11 | +752.71% | Nov 9, 2023 |
Financial Forecast
Revenue This Year
7.14M
from 9.16M
Decreased by -22.05%
Revenue Next Year
8.67M
from 7.14M
Increased by 21.43%
EPS This Year
-1.58
from -1.63
EPS Next Year
-1.37
from -1.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.7M | 21.0M | 42.0M | 157.5M | 176.4M |
| Avg | 7.1M | 8.7M | 13.8M | 38.5M | 79.7M |
| Low | n/a | n/a | n/a | n/a | 13.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 60.5% | 194.1% | 384.4% | 1,043.8% | 357.9% |
| Avg | -22.1% | 21.4% | 58.8% | 179.7% | 106.8% |
| Low | - | - | - | - | -64.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.50 | -1.16 | -1.03 | -0.24 | -0.28 |
| Avg | -1.58 | -1.37 | -1.27 | -1.35 | -0.78 |
| Low | -1.66 | -1.44 | -1.35 | -2.17 | -1.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.